Combining Molecularly Targeted Agents: Is More Always Better?
MetadataShow full item record
The concurrent targeting of critical nodes along key signaling pathways with molecularly targeted agents is a rational antitumor strategy, which has had varying degrees of success. Combinatorial challenges include overcoming synergistic toxicities and establishing whether combinations are truly active, to make "go, no-go" decisions to proceed to later phase trials. Clin Cancer Res; 23(5); 1123-5. ©2016 AACRSee related article by Calvo et al., p. 1177.
Version of record
Medicine Drug Development Unit (de Bono)
Gastrointestinal Cancer Biology and Genomics
License start date
Clin Cancer Res, 2017, 23 (5), pp. 1123 - 1125